Renowned Cardiologist Dr Luca Testa Highlights the Effectiveness of Abluminus DES+ in Complex Angioplasty Cases

“Abluminus DES+ has been my choice of stent for many years, particularly in complex cases, and the results have been promising,” stated Dr. Luca Testa during a press conference. “This unique combination of a drug-coated balloon and a bioresorbable polymer sirolimus-eluting stent offers distinct advantages, especially when treating complex and diffuse disease. It is noteworthy that interventional cardiology is undergoing a significant paradigm shift. Despite the availability of advanced DES technologies like Abluminus DES+, we are progressively changing our approach, considering alternative options such as the Sirolimus-coated balloon Magic Touch. I firmly believe that in the future, we will witness a further implementation of drug-coated balloon technology in our daily practice, either alongside or even independently of stent usage. Abluminus is undoubtedly one of the finest technologies available, especially for complex cases.”

Dr. Luca Testa’s workshops have provided valuable insights into the efficacy and potential of Abluminus DES+ in complex angioplasty procedures. With these educational initiatives, Concept Medical and Dr Testa aim to enhance the knowledge and expertise of healthcare professionals in India, ultimately leading to improved patient outcomes and advancing the field of interventional cardiology.

Explaining the innovation, Concept Medical’s Founder & MD, Dr Manish Doshi, said, “In several patients with type II diabetes and coronary heart disease, there is as recurrence of major adverse cardiac events (MACE) like heart attack, stroke and restenosis (narrowing of unblocked artery after operation). This abluminal drug-eluting stent DES+ will considerably reduce the chances of recurrence.”

About Dr. Luca Testa:

Dr. Luca Testa is a renowned interventional cardiologist at IRCCS Policlinico San Donato – Milan, Italy. With extensive experience in complex coronary interventions, Dr. Testa has been instrumental in the development and advancement of novel treatment options in the field of interventional cardiology.

If you have any objection to this press release content, kindly contact pr.error.rectification[at]gmail.com to notify us. We will respond and rectify the situation in the next 24 hours.